Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Merck & Company (MRK – Research Report), ...

Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...

With a market cap of $258 billion, Merck & Co., Inc. (MRK) is a global healthcare company, operating in the pharmaceutical and animal health sectors. Based in Rahway, New Jersey, Merck develops ...

Merck & Co Inc (NYSE:MRK) reported a 4% increase in revenues for the quarter, or 7% on a constant currency basis, driven by strong performance in key areas like Oncology and Animal Health.

Merck CEO Robert Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, ...

Merck & Company ( (MRK) ) has released its Q3 earnings. Here is a breakdown of the information Merck & Company presented to its ...

In a report released yesterday, Mohit Bansal from Wells Fargo assigned a Hold rating on Merck & Company (MRK – Research Report), ...

Innovative technology represents a breakthrough scientific achievement for one of the most common feline infectious diseases RAHWAY, N.J., September 24, 2024--(BUSINESS WIRE)--Merck Animal Health, ...